Week 111 Review - Another bad week

Two bad weeks in a row is disheartening. After such rapid gains I was hoping things would stabilise, but following last week's £3,204 drop, this week saw a further drop of £2,400. The combined portfolios are still ahead by £3,387 with a value of £73,695 but that's a long way down compared to just over 3 weeks ago when they briefly topped £80,000.

Worst performer this week was AMYT:Amryt Pharma. An unexpected placing caused the share price to drop by 21%. Fortunately they are still 12% in profit, but as one of my biggest holdings this was responsible for most of my losses.

IQE:IQE only dropped a little this week, but in my ISA it was 15% of my purchase price and my SIPP holding bought at a "bargain" 131p is now losing £122.

WRES:W Resources reversed recent gains and dropped by 7% so my improved optimism last week was a tad premature.

It wasn't all bad news. REDS:RedstoneConnect increased by 7% in my trading account after announcing a big contract win. These are still down by 30% though.

MTFB:Motif Bio also climbed 7% and went into profit for the first time since my recent purchase. Could I have actually timed it right on this one? They are now up by 6%.

Share of the Week was RED:RedT Energy which has had a torrid run of late, but announcement of some orders and recruitment of quality staff from a rival that's gone into administration caused the share price to increase by 17%. Still a way to go to get into profit, as they are 14% down, but another week like this one will see them go green.

Possibly my worst ever 2 weeks!

The ISA and share accounts look like this

			Weekly Change
Cash	£43.34		+£0
Portfolio cost	£44,426.84		+£0
Portfolio sell value (bid price - commission)	£46,673.12	(+5.1%)	-£1,874.08
Potential profits	£8,084.95		-£1,517.33
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£585.38		+£0
Yr 3 Average monthly cash profit	£332.18	(9%)	-£55.37
Total Dividends	£1,179.05		+£0
Total Profit from sales	£7,297.85		+£0
Average monthly cash profit	£326.67	(8.8%)	-£2.97
(Sold stocks profit + Dividends - Fees / Months)

My biggest holdings of OPTI:Optibiotix, IQE:IQE and AMYT:Amryt Pharma all dropped in value this week and hammered the portfolio value. Most of it was reduced profits, but OPTI:Optibiotix is now back to causing deepening losses. My week 1 sale has now averaged out across the 7 weeks and I suspect next week will see year 3 drop to below average performance for sales and dividends.

Bleak - not much buffer left, but when I look back across the last 2 years, things are better now than they have been for most of my short investment career. My big concern is the total reliance on IQE:IQE. Without the £6,284 potential profit, my portfolio would be horribly in the red.

The SIPP looks like this after week 95

			Weekly Change
Cash	£54.80		+£33.88
Portfolio cost	£25,218.51		+£0
Portfolio sell value (bid price - commission)	£26,503.49	(5.1%)	-£562.75
Potential profits	£2,577.81		-£345.44
Yr 2 Dividends	£328.84		+£33.88
Yr 2 Profit from sales	£6,575.33		+£0
Yr 2 Average monthly cash profit	£688.11	(32.7%)	-£12.89
Total Dividends	£708.15		+£33.88
Total Profit from sales	£8,925.19		+£0
Average monthly cash profit	£435.18	(20.7%)	-£3.07
(Sold stocks profit + Dividends - Fees / Months)

Nowhere near as dramatic a loss as last week, with small drops for IQE:IQE and OPTI:Optibiotix and a decent rise of 4% for LGEN:Legal & General helping mitigate the losses. LGEN:Legal & General also stumped up a £33.88 interim dividend which was nice.

Still going down, but not as alarming as that horrible spike.

The trading account looks like this after week 61

			Weekly Change
Cash	£79.63		+£0
Portfolio cost	£486.05		+£0
Portfolio sell value (bid price - commission)	£341.11	(-29.8%)	+£36.14
Potential profits	£0		+£0
Dividends	£1.15		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£1.54	(-3.8%)	+£0.03
(Sold stocks profit + Dividends - Fees / Months)

Good news form REDS:RedstoneConnect saw a 7% rise and a glimmer of hope.

Still looks rubbish!

Much excitement at the end of the week when CAML:Central Asia Metals announced the details of their reverse takeover of Lynx Resources. This was a huge purchase and included a placing, but they have bought into a profitable company that should see a significant rise in both profits and share price. Dividends will be affected in the short term which is a shame, but their interim results announced on the same day will see one last socking great dividend paid in October.

The suspension on share trading will be lifted on Monday, so it will be fascinating to see what happens. It will either see a drop of 22p to the placing price of 230p or potentially a healthy rise on the prospects of significantly more earnings in the future and maybe a main market listing.

Week 110 Review - Reversal of fortunes

This has been an incredibly volatile week. There were some great gains which will provide long term stability to the portfolio, but big losses in two of my main holdings resulted in a drop in overall portfolio value of £3,204. The combined value drops to £76,066 and the buffer between profit and loss narrows to £5,788. Hard to believe it was only 6 trading days ago that the portfolio value topped £80,000.

Worst performer by a long way was IQE:IQE. The recent bargain purchase in my SIPP had the 14% profits wiped out to a 2% loss so maybe not such a bargain after all. My ISA holding was 406% up but that got smashed by 70% to 336%. It's really difficult to see why the launch of the new iPhone should have had such a negative effect. It changes nothing. No doubt the shorters will be rubbing their hands in glee. There were almost 14m shares traded on Friday so there's no doubt the volume is there, but the iPhone launch must have triggered a lot of profit taking. I'm hoping things will settle around the 150p level rather than the 100p level though.

Next worst performer was even more baffling. OPTI:Optibiotix dropped 11% despite news of a groundbreaking deal with Bened Biomedical. Not only does it give them the rights to distribute Optiobiotix strains in South east Asia, if gives Optibiotix the right to market their strains focussed on neuropsychological, allergic, immunological, metabolic and aging-related disorders. This effectively adds a whole raft of potential new products to the portfolio. How can that result in an 11% drop in share price?

As if to match this, SBTX:SkinBioTherapeutics also dropped 11% for no apparent reason, although to be fair there was no apparent reson for last week's rise either.

To add to the gloom of the big losses above, KIBO:Kibo Mining dropped 7% and ARL:Atlantis Resources seems to be in free-fall, dropping 6% on news that there are not going to be any further government subsidies to support the MeyGen project. It would be nice to see some figures that suggest we don't need it.

To counter all that misery, there were some really good gains this week, but not enough to prevent the financial losses from the fall in larger holdings.

CWR:Ceres Power Holdings continues a very slow and gradual rise, climbing another 6% to go 50% up on purchase price. At some point soon there will be news of an actual contract, which could see a significant re-tate if with a multi-national.

WRES:W Resources also continues an unusually steady climb for a small-cap miner, up another 7% this is now only 24% down and may lose the red colouring for an amber shade in the next few weeks.

RED:RedT Energy is also waking a little after a truly dreadful run recently. A climb on 7% means these are now 31% down. Only news of actual orders will cause this to recover.

MTFB:Motif Bio recovered all the losses since I bought them and climbed 11% to only be 1% down. News of orphan drug status really helped this at the end of the week, so I'm hoping with phase 3 trials complete there will be good news in the next few months.

JLP:Jubilee Platinum is also doing a gradual creep upwards. These gained 12% and are now only 1% down following an upbeat webcast and a feeling that news is imminent on both new deals and a way forward for Tjate.

Share of the Week was a massive help in preventing much bigger losses, as AMYT:Amryt Pharma is one of my largest holdings and climbed by 16% to go 33% up.This has been on a positive move ever since the interims revealed how much money Lojuxta is bringing in and the potential for short term growth enabling this to make a significant contribution to completing the phase 3 trials of AP101. There was also excitement around the presentation given in New York on Tuesday 12th that may have brought Amryt to the attention of American investors and contributed to the rise.

So quite a lot happened!

Ouch! Maybe it had got a wee bit ahead of itself. I just hope next week isn't as bad as this one for the big two.

Here's the ISA and share account performance

			Weekly Change
Cash	£43.34		+£0
Portfolio cost	£44,426.84		+£0
Portfolio sell value (bid price - commission)	£48,547.20	(+9.3%)	-£1,265.04
Potential profits	£9,602.28		-£1,057.66
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£585.38		+£0
Yr 3 Average monthly cash profit	£387.55	(10.5%)	-£77.51
Total Dividends	£1,179.05		+£0
Total Profit from sales	£7,297.85		+£0
Average monthly cash profit	£329.64	(8.9%)	-£3.03
(Sold stocks profit + Dividends - Fees / Months)

The drop in value was less than last week's gain, so I'm still up over the last 2 weeks. The risies in AMYT:Amryt Pharma really helped reduce the impact of the losses in IQE:IQE and OPTI:Optibiotix. Unfortunately OPTI:Optibiotix has plummeted to a £770 loss in these accounts so was responsible for both reduced profit and deepening loss. Year 3 profits are coming down to more normal figures now we're 6 weeks into the year. Soon they'll drop below average and I'll need to contemplate selling something, but I'm reluctant to when the paper profits are doing so well.

There's still a more healthy gap than there has been for 2 years so I won't panic just yet.

The SIPP looks like this after week 94

			Weekly Change
Cash	£20.92		+£0
Portfolio cost	£25,218.51		+£0
Portfolio sell value (bid price - commission)	£27,066.24	(7.3%)	-£1,928.54
Potential profits	£2,923.25		-£1,857.91
Yr 2 Dividends	£294.96		+£0
Yr 2 Profit from sales	£6,575.33		+£0
Yr 2 Average monthly cash profit	£701.00	(33.4%)	-£17.09
Total Dividends	£708.15		+£0
Total Profit from sales	£8,925.19		+£0
Average monthly cash profit	£438.25	(20.9%)	-£4.71
(Sold stocks profit + Dividends - Fees / Months)

Absolute carnage. The SIPP only has 7 stocks, and CAML:Central Asia Metals is still suspended. The only one that increased in value this week was WRES:W Resources and that's such a tiny holding it had no impact on the declines in OPTI:Optibiotix and IQE:IQE which are bigger holdings than all the other non-suspended shares. Average profit is still twice target so no plans on selling anything.

It has been a spectacular rise over the last few weeks, but I wasn't counting on such a spectacular reversal.

I'd better go through the motions of documenting the trading account after week 60

			Weekly Change
Cash	£79.63		+£0
Portfolio cost	£486.05		+£0
Portfolio sell value (bid price - commission)	£304.97	(-37.3%)	-£11.12
Potential profits	£0		+£0
Dividends	£1.15		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£1.57	(-3.9%)	+£0.02
(Sold stocks profit + Dividends - Fees / Months)

The slow and relentless creep downwards continues. I'm seriously contemplating selling this at a loss and learning my lesson - the whole point of this account was to buy for short term gain, but I've treated it like an investment. To do this properly I need tighter stop losses to bail at the first sign of a dip and move on to something else. I've utterly failed to differentiate between this account and my other account - in fact I'd go as far as saying I've done more trading in my SIPP than this account. I just can't help feeling REDS:RedstoneConnect has been over sold and will recover quite rapidly on one scrap of news. That's not how trading is meant to work though! If I sold now, I would have £383 to put on something more volatile that's in a dip. I just need to find a share that's clearly being played. Unfortunately the most obvious is OPTI:Optibiotix, but I daren't trade on that as the trading account is actually part of my main share account and I don't know which of my holding would be sold, putting at risk the free shares that may be allocated to my long standing holding. I reckon GVC:GVC Holdings is being played too, but at 850p a share it's too much for my tiny £380.

Hopeless

No results expected next week. There has been a development in the AFPO:African Potash saga. African Agronomix Limited have completed their due diligence on the proposed handover of Lac Dinga and the deadline for other conditions being met was extended to 15th September which has now passed. I think getting some revenue for this resource is my only chance of seeing some form of return on my investment. In fact, the ideal scenario would be African Agronomix buying out AFPO:African Potash entirely, which at the moment they'd be able to do very cheap! Meanwhile I wait with interest to see if anything can be salvaged from this disaster.

Week 109 Review - Another Friday spoiler, but a good week

Why are Fridays nearly always so rubbish?

The combined portfolios were up by £3,350 on the week at the end of play yesterday, but drops in both IQE:IQE and OPTI:Optibiotix today have wiped out a significant proportion of those gains. The portfolios still ended healthily up by £1,919 with a £8,993 buffer between value and cost, but the overall value dropped to £79,270 which is back under the £80,000 milestone I was hoping to pass in today's snapshot.

Worst performer by a mile was IKA:Ilika. This really has been a disaster - dropping 15% this week and now down by 60% and losing £337. I was foolish enough to buy the story without looking at the Board of Directors. Close examination would have revealed a bunch of scientists without a clue how to commercialise anything. They have invented a fantastic battery - shame they haven't sold any! The management here reminds me of TRK:Torotrak and I believe the company will go the same way unless they appoint a Commercial Director.

OPTI:Optibiotix had even more amazing news this week, sealing a new deal with Tata Chemicals. Frustratingly the share price only finished the week up by 1p. Better than being down, but with a distinct air of damp squib.

SBTX:SkinBioTherapeutics did much better than its parent company, climbing 11% probably on the back of the successful OPTI:Optibiotix deals improving confidence that this company can do the same. These are only 12% down on my purchase price now so could be back in profit soon.

Need I say what wins Share of the Week? IQE:IQE climbed 44% in my ISA despite the share price plunging 12% immediately after interims were published. That 12% drop would have been a reduction against my purchase price of 100% in my ISA, as it matched the price I paid for the shares. I bought some in my SIPP that morning, tragically not at the bottom of the dip, but enough that I made a gain of £334 (14%) in 4 days.

The cash was re-invested so cost goes back to where it was, and the gap gets even wider.

The ISA and share portfolios looks like this

			Weekly Change
Cash	£43.34		-£2,403.75
Portfolio cost	£44,426.84		+£0
Portfolio sell value (bid price - commission)	£49,812.24	(+12.1%)	+£1,430.10
Potential profits	£10,659.94		+£1,298.33
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£585.38		+£0
Yr 3 Average monthly cash profit	£465.06	(12.6%)	-£120.32
Total Dividends	£1,179.05		+£0
Total Profit from sales	£7,297.85		+£0
Average monthly cash profit	£332.67	(9.0%)	-£3.23
(Sold stocks profit + Dividends - Fees / Months)

All the cash was moved out to the SIPP, or used for the monthly ISA fee, and the value increased by £1,430 mainly thanks to IQE:IQE with a little help from elsewhere. Nearly all the gains were profit, with SBTX:Skinbiotherapeutics reducing the losses with a nice rise.

The green line has dipped because the cash was removed from the account to the SIPP, but the gap remains wonderful

The SIPP looks like this after week 93

			Weekly Change
Cash	£20.92		+£0.35
Portfolio cost	£25,218.51		+£2,389.88
Portfolio sell value (bid price - commission)	£28,994.78	(15%)	+£503.10
Potential profits	£4,781.16		+£499.21
Yr 2 Dividends	£294.96		+£0
Yr 2 Profit from sales	£6,575.33		+£0
Yr 2 Average monthly cash profit	£718.09	(34.2%)	-£19.02
Total Dividends	£708.15		+£0
Total Profit from sales	£8,925.19		+£0
Average monthly cash profit	£442.96	(21.1%)	-£5.28
(Sold stocks profit + Dividends - Fees / Months)

Big increase in cost from the IQE:IQE purchase and increase in profits thanks to IQE:IQE and a little from OPTI:Optibiotix. LGEN:Legal & General had a bad week which meant the profits weren't as high as they could have been.

Great smashing super

The trading account looks terrible after week 59

			Weekly Change
Cash	£79.63		+£0
Portfolio cost	£486.05		+£0
Portfolio sell value (bid price - commission)	£316.09	(-34.8%)	-£13.90
Potential profits	£0		+£0
Dividends	£1.15		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£1.59	(-3.9%)	+£0.03
(Sold stocks profit + Dividends - Fees / Months)

REDS:RedstoneConnect put out a bloody awful trading statement. There was no bad news - but there was no news either. They may as well have not bothered for all the information it provided, and the share price reacted accordingly and is even worse than it's been for the last few months. This has been a very harsh lesson on the importance of ignoring bulletin board hype as I fell for it hook, line, sinker and copy of the Angling Times!

Not great, smashing or super

Next Tuesday sees the likely launch of the iPhone 8 and all the associated hype that could support the scarily high IQE:IQE share price. That support was distinctly lacking today though. No other news expected but who knows what will come?

IQE and Optibiotix just won't stop climbing

Yesterday was exciting and I wondered what the rest of the week would throw at us, and today it threw plenty.

IQE:IQE seems unstoppable, climbing another 5.75p and providing £374 (16%) potential profit in the 2 days I've owned them in my SIPP.

That's nothing compared to my ISA holding, which is going crazy and is now making £8,086 (413%) potential profit.

That would be enough to make me deliriously happy on its own, however the OPTI:Optibiotix bid price climbed another 3.5p today. This has gone from Nemesis Share making a loss of £4,500 just a few months ago to £3,374 paper profit today. At this rate of growth it will soon overtake IQE:IQE as Star Share!

The effect on the combined portfolios has seen another significant milestone reached, with the total value passing £80,000. That won't be an official figure unless it lasts until Friday and gets on the snapshot graph, so I just need things to stabilise a bit for the rest of the week.

Still no news following the CAML:Central Asia Metals suspension. I felt obliged to post on their bulletin board:

"CAML has a superb track record of putting shareholders first. Don't forget, they've paid out more in dividends than they generated from the IPO.

I really don't believe they would be considering this unless in the shareholders' best interests.

CAML are a cautious company - as their approach to Copper Bay demonstrates.

I'm more excited about what could be an amazing opportunity than I am nervous about being shafted."

Now I just need to hope it's all true! I'm really hoping this is a buy-out of a bigger company. No corresponding publicly listed companies have had their shares suspended though, so it points to a private company. Just a waiting game now.

This week could easily smash the record of best ever week - but there are still 2 days to go and all sorts of horrors could unfold. Roll on 8am...

IQE excitement

What a day!

In fact what a week - and we're only 2 days into it.

Everything was focused on IQE:IQE this morning. My £2,400 had been transferred into the SIPP on Monday and a limit order set up for 115p.

I awaited the results with trepidation - would my prediction come true and the share price plummet immediately after the RNS like it did back in March?

Yes!

Revenue was up but profits were slightly down - exactly the combination to cause an initial panic for people who don't read the outlook, which is a thing of great beauty and which triggered the immediate buy-back after the dip.

Unfortunately the price only plummeted 12% to 121p so my 115p limit order didn't get reached. When I saw the price heading up again I dashed to the PC but by the time I had logged in the price was up to 131.45p. I knew I should have gone for a 125p limit, but got greedy and paid the price. Still, 6p a share isn't a massive difference and I still got them a lot cheaper than if I had bought yesterday.

As predicted, the price soared from that point. I wonder if the shorters started closing their positions once it started heading up from 121p?

The SP ended up at 146.75p bid price, 15.3p up on my purchase price. That meant my 1,809 shares purchased for £2,389.88 made £252 (11%) paper profit on day 1 - yippee!

What's even more exciting is my original holding of 6,550 shares purchased at 29.59p ended the day £7,644 (391%) in profit.

It was great news all round, with OPTI:Optibiotix announcing an agreement with Tata Chemicals which saw a reversal of yesterdays decline, although the share price still doesn't want to rocket like I thought it would following news of this magnitude.

Then JLP:Jubilee Platinum revealed an improved contract with Dilokong Chrome Mines to increase their benefit from chrome sales from 0% to 50%. Amazingly this caused no change in the share price - I just don't know what it will take for this to get back into profit!

All this came on the back of yesterday, which delivered a strong set of interims for AMYT:Amryt Pharma triggering 2 days in the blue and taking them to £1,431 (23%) potential profit..

Most striking was the suspension of CAML:Central Asia Metals as they are in advanced negotiations for a reverse takeover bid. There are no details, but if they are buying out a larger company, then this deal could be transformational. I'm really glad I increased my holding just last week to 2,678 shares, although who knows how long they will be in limbo?

All this excitement leaves the combined portfolios up by £1,145 on the week after being down over £1,000 at the end of yesterday, and total value is now £78,496 putting them £8,218 in the black. It would only take a rise of 3.5p for OPTI:Optibiotix, and the portfolio value will get past £80,000 only 2 weeks after passing £75,000.

I don't think there have ever been 2 consecutive days with so much significant news and action for the biggest holdings in my portfolio. What else can this week throw at us?...

Week 108 Review - New record high

The week started off really badly and I thought a big chunk of recent gains was gone, but the last 2 days really turned around and things are looking much better after today. As I've sold some shares and am holding the cash until I can transfer it to my SIPP, I decided to make a subtle change to the overall portfolio value and include cash. Most of the time this is negligible, but not this week.

Combined portfolio value compared to cost has increased by £1,976 this week and a grand total of £77,361 is a new high. The buffer between profit and loss is now a massive £7,073 so I'm hopeful I can remain in the black for a while.

Only one double-digit loser this week and it's CWR:Ceres Power Holdings which dropped 12%. This is still 41% up and making £753 potential profit so I can tolerate the odd dip.

Although OPTI:Optibiotix only climbed 4% this week to 73p bid price, I have such a vast sum invested that it generated most of the profits. All three accounts are now in profit, with the share account up 9%, ISA up 3% and SIPP up 12% following the huge purchase at sub 60p a few weeks ago. Total paper profit is already £2,275 making it my 2nd best performing share just a month after being well entrenched as Nemesis Share. Stress has turned to absolute excitement now the brakes are off.

Nemesis Share is now LOOK:Lookers, down 39% after the Brexit crash and losing £801. I really can't believe this will continue trading on a P/E ratio of 5.4 though - it's a FTSE250 company for goodness sake!

Making up for last week, AMYT:Amryt Pharma did well and climbed 8% on the lead up to interim results on Monday. These are up by 15% and making £924 potential profit.

Share of the Week was a bit of a surprise. WRES:W Resources climbed 11% in my ISA and 16% in my SIPP. Is it possible they might actually produce something at some point? I had almost written these off, but maybe there is some hope. I think the main reason for the climb was that the remaining funding required has been secured through debt rather than dilution - and with 4,842,640,000 shares in circulation it couldn't get much more dilute. I'm down by 50% in my ISA and 33% in my SIPP, so still stuck with them for a long while yet. Total invested was £633 so a bit more than I usually punt on a minuscule miner, but that did buy me 98,735 shares which in those days felt amazing.

Biggest ever gap, but it will close up a bit when I buy some shares next week with the cash from yesterday's sale.
Here's the ISA and share account performance

			Weekly Change
Cash	£2,447.09		+£2,405.53
Portfolio cost	£44,426.84		-£2,369.41
Portfolio sell value (bid price - commission)	£48,382.14	(+8.9%)	+£1,064.58
Potential profits	£9,361.61		+£751.44
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£585.38		+£36.11
Yr 3 Average monthly cash profit	£585.35	(15.8%)	-£142.96
Total Dividends	£1,179.05		+£0
Total Profit from sales	£7,297.85		+£36.11
Average monthly cash profit	£335.90	(9.1%)	-£1.67
(Sold stocks profit + Dividends - Fees / Months)

So the sale of BDEV:Barratt Developments and KIBO:Kibo Mining from my share account liberated £2,405 in cash and made a huge £36 profit. As a result of not re-investing, the portfolio cost has dipped by £2,369 and this will never re-appear on this balance sheet as £2,400 will be transferred to my SIPP on Monday. Taking into account the sale, the rest of the portfolio climbed by £1,064, most of which was due to OPTI:Optibiotix and AMYT:Amryt Pharma. IQE:IQE stayed pretty flat this week. Year 3 performance continues to tumble after the week 1 sale, and overall performance only drops by £1.67 a month thanks to this week's sale.

The graph has never done that before! Long may this gap remain.

The SIPP looks like this after week 92

			Weekly Change
Cash	£20.57		+£0
Portfolio cost	£22,828.63		+£0
Portfolio sell value (bid price - commission)	£26,101.80	(14.3%)	+£911.57
Potential profits	£4,281.95		+£833.56
Yr 2 Dividends	£294.96		+£0
Yr 2 Profit from sales	£6,575.33		+£0
Yr 2 Average monthly cash profit	£737.11	(38.7%)	-£18.90
Total Dividends	£708.15		+£0
Total Profit from sales	£8,925.19		+£0
Average monthly cash profit	£448.24	(23.6%)	-£4.92
(Sold stocks profit + Dividends - Fees / Months)

OPTI:Optibiotix and CAML:Central Asia Metals caused the £833 rise in potential profit, but LGEN:Legal & General dropped 2% and dented that a little. TRX:Tissue Regenix and WRES:W Resources both climbed a bit to cut the losses and contribute to a rise in value of £911. Monthly performance is way ahead of target. Things will hot up here next week when I inject the £2,400 and in a few months the nice tax man will deliver another £600 as a result.

It's all so encouraging - should I be worried it won't last?

The trading account looks utterly dire after week 58

			Weekly Change
Cash	£79.63		+£0
Portfolio cost	£486.05		+£0
Portfolio sell value (bid price - commission)	£329.99	(-32.1%)	+£0
Potential profits	£0		+£0
Dividends	£1.15		+£0
Profit from sales	-£22.85		+£0
Average monthly cash profit	-£1.62	(-4.0%)	+£0.03
(Sold stocks profit + Dividends - Fees / Months)

Oh the unbearable tedium...

Move along please - there's nothing to see here.

That's another week out of the way, and I'm most excited that I have a big pile of cash to invest next week. Will IQE:IQE tank after their results? Will I be able to grab a bargain? Will the shorters keep increasing their bets and make a downward push inevitable? I can but hope - even though it will wipe loads off my ISA holding, it will only be for a few weeks. In fact, after their finals it only dipped for a day, so there's no hanging around if I want a bargain.

I was so relieved I didn't set a stop loss last time around else I would have been chucked out and never got back in without decreasing the number of shares. I don't trust the market makers not to batter the share price on the slightest negativity in an attempt to trigger a load of stops and get their hands on thousands of shares just before the price bounces back. Maybe I'm being over-cynical, but I've seen enough suspicious activity over the last 2 years to be wary. If that does happen then the shorters are likely to take that as a signal to close their positions and buy all those shares causing a massive re-rate upwards.

I may have to pick a value I'm happy to pay and set a buy limit at that level so if the price becomes available while I'm at work I won't miss out. I think 110p would be a steal, and that was the last resistance point before the recent rise. Maybe 115p would be safer so I can buy on the way down as it may not stop at 110p for long enough.

On the other hand, the share price could absolutely rocket and the shorters panic and take their losses. If that happens I'm doomed and will never buy in time. I'll be happy that my ISA profits have soared and buy something else. At the moment I'm leaning towards £1,400 more CAML:Central Asia Metals which is the best run company in my portfolio and hasn't increased enough given the copper price rise. I'd also get £1,000 KAT:Katoro Mining as they are ahead of schedule and stupidly cheap given the expertise of their CEO and ties to KIBO:Kibo Mining. I was hoping for a load of free KAT:Katoro Mining shares as a result of my KIBO:Kibo Mining holding, but if they do arrive it will be a long way down the line, so may as well get a few now before they re-rate.

Lots to look forward to next week...